ClinicalTrials.gg
CompletedNCT03309111Updated Jun 13, 2024

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

A Phase 1 interventional study of ISB 1342 in Relapsed/Refractory Multiple Myeloma, sponsored by Ichnos Sciences SA. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by Ichnos Sciences SA · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 377 studies in Multiple Myeloma with a site in France — 73 open to participants now, 137 under way, 49 of them phase 3. Multiple Myeloma · France.

Enrollment
201st of 316
81 · median 138
Started
2017
with 20 others
Phase 1
60 of 377
9 open now
Registered
174th of 377
by date

Among the 377 studies in Multiple Myeloma with a site in France, this one is the 201st largest by enrollment of the 316 interventional ones that give a count, is one of 21 that started in 2017, is one of 60 in phase 1, and was the 174th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

73 of the 377 studies in Multiple Myeloma with a site in France are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Multiple Myeloma with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.

Read the detailed description

This study is an open-label, multi-center, Phase 1 study of ISB 1342 in subjects with relapsed/refractory multiple myeloma refractory to proteasome inhibitors (PIs), immunomodulators (IMiDs), and daratumumab. There will be a dose escalation phase (Part 1) and dose expansion phase (Part 2). In Part 1 of the study, subjects will be treated at escalating dose levels. Once the recommended part 2 dose (RP2D) of ISB 1342 is declared in Part 1, the expansion phase (Part 2) will be initiated at the RP2D.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of multiple myeloma with (serum, urine, or free light chain) per International Myeloma Working Group (IMWG) criteria, including non-secretory or oligo-secretory multiple myeloma which has after or is refractory to prior therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-CD38 targeted therapies (daratumumab, isatuximab).
  • (ECOG) performance-status score of 2 or less and 1 or less (for France).
  • Adequate hematologic, renal, and hepatic functions
  • Seronegative for antigen; positive hepatitis B tests can be further evaluated by confirmatory tests, and if viral load is negative, the subject can be enrolled.
  • Seronegative for antibody; if positive, then further test for the presence of antigen by hepatitis C virus polymerase chain reaction (HCV PCR). If HCV antigen tests are negative, then the subject can be enrolled.
  • Oxygen saturation level ≥92% on room air.
  • (LVEF) ≥50% and no pericardial or pleural effusion at Screening

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system involvement
  • Exposure to daratumumab or isatuximab within 2 months prior to the start of study treatment
  • Active plasma cell leukemia
  • Active infectious disease
  • cardiovascular and respiratory conditions
  • History of infection
  • Subjects requiring prohibited concomitant medications
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    ISB 1342

    Part 1: Cohorts of multiple ISB 1342 dose levels; Part 2: One dose regimen until disease progression or other discontinuation criterion is met

    Biological: ISB 1342

Interventions

  • BiologicalISB 1342

    ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)

06

What researchers measure

Primary outcomes

  1. Maximal tolerated dose (MTD) and/or recommended part 2 dose (RP2D) of ISB 1342 (Part 1)

    Time frame: 28 days

  2. Proportion of subjects with an investigator-assessed objective response (at least a partial response or better), complete response, disease control (stable disease or better) to ISB 1342, per International Myeloma Working Group (IMWG) criteria (Part 2)

    Time frame: 28 days

Secondary outcomes

  1. Number of subjects with adverse events based on frequency and severity as assessed by common terminology criteria for adverse events (CTCAE) v5.0 (Part 1 and Part 2)

    Time frame: up to 30 days post last dose

  2. Maximum serum concentration (Cmax) of ISB 1342 (Part 1 and Part 2)

    Time frame: 28 days

  3. Time to reach maximum observed plasma concentration (Tmax) of ISB 1342 (Part 1 and Part 2)

    Time frame: 28 days

  4. Area under the serum concentration time curve from zero to time t (AUC0-t) of ISB 1342 (Part 1 and Part 2)

    Time frame: 28 days

  5. Area under the curve from time zero to end of dosing interval (AUC0-tau) of ISB 1342 (Part 1 and Part 2)

    Time frame: 28 days

  6. Immunogenicity of ISB 1342 by anti-drug antibody (ADA) formation (Part 1 and Part 2)

    Time frame: 28 days

  7. Percent incidence of neutralizing antibody formation from positive anti-drug antibody (ADA) samples assessed from baseline until end of treatment (EOT) (Part 1 and Part 2)

    Time frame: 28 days

  8. Efficacy of ISB 1342 (duration of response [DOR]) (Part 1 and Part 2)

    Time frame: 28 days

  9. Efficacy of ISB 1342 (disease control rate [DCR]) (Part 1 and Part 2)

    Time frame: 28 days

  10. Efficacy of ISB 1342 (duration of disease control) (Part 1 and Part 2)

    Time frame: 28 days

  11. Efficacy of ISB 1342 (time to minimal residual disease [MRD] negative status) (Part 1 and Part 2)

    Time frame: 28 days

  12. Efficacy of ISB 1342 (progression free survival [PFS]) (Part 2)

    Time frame: 28 days

  13. Efficacy of ISB 1342 (time to treatment failure [TTF]) (Part 2)

    Time frame: 28 days

  14. Efficacy of ISB 1342 (time to disease progression [TTP]) (Part 2)

    Time frame: 28 days

  15. Efficacy of ISB 1342 (overall survival [OS]) (Part 2)

    Time frame: Time from first dose until death from any cause or end of study collection, whichever is later, assessed up to 60 months.

  16. Proportion of subjects with investigator-assessed objective response (at least a partial response or better), complete response, disease control (stable disease or better) to ISB 1342, per International Myeloma Working Group (IMWG) criteria (Part 1)

    Time frame: 28 days

07

Study locations

20 sites
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21287, United States
  • Mayo Clinic Cancer Center (MCCC) - Rochester
    Rochester, Minnesota 55905, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Mount Sinai Beth Israel
    New York, New York 10029, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Duke Clinical Research Institute
    Durham, North Carolina 72205, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • CHU de Nantes - Hôtel-Dieu
    Nantes, Cedex 44093, France
  • CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
    Pessac, Cedex 33604, France
  • Centre Hospitalier Lyon-Sud
    Pierre Benite, Cedex 69495, France
  • CHU de Poitiers
    Poitiers, Cedex 86021, France
  • CHU de Rennes - Hôpital Pontchaillou
    Rennes, Cedex 35033, France
  • Institut Universitaire du Cancer de Toulouse - Oncopole
    Toulouse, Cedex, France
  • CHRU de Tours - Hôpital Bretonneau
    Tours, Cedex 37044, France
  • CHU Hôpital Henri Mondor
    Créteil, 94010, France
  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
    Lille, 59000, France
  • L'Institut Paoli - Calmettes
    Marseille, 13009, France
  • Hôpital Saint-Antoine
    Paris, 75012, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2023, 73 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 73 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2017
First posted
Oct 13, 2017
StartActual
Oct 25, 2017
Primary completionActual
Dec 15, 2023
CompletionActual
Dec 15, 2023
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03309111
Lead sponsor
Ichnos Sciences SA
Collaborators
Glenmark Pharmaceuticals S.A.
Responsible party
Sponsor
First posted
Oct 13, 2017
Start date
Oct 25, 2017
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023
Last update
Jun 13, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion